Europese Unie - Nederlands - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Europese Unie - Nederlands - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

beaphar bv - fipronil - spot-on oplossing - fipronil 134 mg/ml, - fipronil - honden

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

beaphar bv - fipronil - spot-on oplossing - fipronil 268 mg/ml, - fipronil - honden

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

beaphar bv - fipronil - spot-on oplossing - fipronil 402 mg/ml, - fipronil - honden

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

beaphar b.v. - fipronil - spot-on oplossing - fipronil 100 mg/ml, - fipronil - honden

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

beaphar b.v. - fipronil - spot-on oplossing - fipronil 50 mg/stuk, - fipronil - katten

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

air liquide santé international 75, quai d'orsay f-75007 paris (frankrijk) - zuurstof, medicinaal 20,9 % - medicinaal gas, samengeperst - stikstof (e 941), - medical air

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

air products nederland b.v. boyneweg 10 3197 lk rotterdam - zuurstof, medicinaal 22 % - medicinaal gas, samengeperst - stikstof (e 941), - oxygen

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sol spa via borgazzi 27 20900 monza (mi) (italiË) - zuurstof, medicinaal 21,75 % v/v - medicinaal gas, samengeperst - stikstof (e 941), - medical air